Circulating tumor cells (CTCs) are tumor cells that have sloughed off the primary tumor and
extravasate into and circulate in the blood. Understanding of the metastatic cascade of CTCs …

Given that cancer mortality is usually a result of late diagnosis, efforts in the field of early
detection are paramount to reducing cancer-related deaths and improving patient outcomes …

Single-cell technologies have contributed to unravelling tumour heterogeneity, now
considered a hallmark of cancer and one of the main causes of tumour resistance to cancer …

From a clinical, morphological and molecular perspective, prostate cancer is a
heterogeneous disease. Primary prostate cancers are often multifocal, having …

The analysis of tumor cells or tumor cell products obtained from blood or other body fluids
(“liquid biopsy”[LB]) provides a broad range of opportunities in the field of oncology. Clinical …

Droplet microfluidics has revolutionized the study of single cells. The ability to
compartmentalize cells within picoliter droplets in microfluidic devices has opened up a wide …

The genomics of primary prostate cancer differ from those of metastatic castration-resistant
prostate cancer (mCRPC). We studied genomic aberrations in primary prostate cancer …

Circulating tumor cell (CTC)-based liquid biopsies provide unique opportunities for cancer
diagnostics, treatment selection, and response monitoring, but even with advanced …

New non-invasive approaches that can complement and improve on current strategies for
colorectal cancer (CRC) screening and management are urgently needed. A growing …

Metastatic biopsy programmes combined with advances in genomic sequencing have
provided new insights into the molecular landscape of castration-resistant prostate cancer …